Citations (47)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (8)
Zhang Tao, Xingwang Kuai, Guangwei Wang, Sanfeng Liu, Kai Liu, Heng Zhang, Shujing Xia & Hua Zhu. (2022) Combination of chemotherapy and immune checkpoint therapy by the immunoconjugates-based nanocomplexes synergistically improves therapeutic efficacy in SCLC. Drug Delivery 29:1, pages 1571-1581.
Read now
Read now
Fabio Perrotta, Vittorio Chino, Valentino Allocca, Vito D’Agnano, Chandra Bortolotto, Andrea Bianco, Angelo Guido Corsico & Giulia Maria Stella. (2022) Idiopathic pulmonary fibrosis and lung cancer: targeting the complexity of the pharmacological interconnection. Expert Review of Respiratory Medicine 16:10, pages 1043-1055.
Read now
Read now
Yihui Fan, Qing Wang, Minxin Shi, Guanjun Ju, Haimin Lu, Liyun Zheng, Jian Chen, Xiaomei Zhou, Ting Xiao & Saihua Chen. (2022) Circ_0020123 promotes NSCLC tumorigenesis via up-regulating KIAA1522 expression through miR-940. Cell Cycle 21:9, pages 894-907.
Read now
Read now
Danilo Rocco, Luigi Della Gravara, Ciro Battiloro, Paolo Maione & Cesare Gridelli. (2021) The treatment of advanced lung adenocarcinoma with activating EGFR mutations. Expert Opinion on Pharmacotherapy 22:18, pages 2475-2482.
Read now
Read now
Mingjun Li, Qianqian Wang, Xiaofei Zhang, Ningning Yan & Xingya Li. (2021) CircPUM1 promotes cell growth and glycolysis in NSCLC via up-regulating METTL3 expression through miR-590-5p. Cell Cycle 20:13, pages 1279-1294.
Read now
Read now
Linying Wei & Jianyang Jiang. (2021) Targeting the miR-6734-3p/ZEB2 axis hampers development of non-small cell lung cancer (NSCLC) and increases susceptibility of cancer cells to cisplatin treatment. Bioengineered 12:1, pages 2499-2510.
Read now
Read now
Liang Kong, Shi-meng Zhang, Jia-hao Chu, Xin-ze Liu, Lu Zhang, Si-yu He, Si-min Yang, Rui-jun Ju & Xue-tao Li. (2020) Tumor Microenvironmental Responsive Liposomes Simultaneously Encapsulating Biological and Chemotherapeutic Drugs for Enhancing Antitumor Efficacy of NSCLC. International Journal of Nanomedicine 15, pages 6451-6468.
Read now
Read now
Danilo Rocco, Vanesa Gregorc, Luigi Della Gravara, Chiara Lazzari, Giovanni Palazzolo & Cesare Gridelli. (2020) New immunotherapeutic drugs in advanced non-small cell lung cancer (NSCLC): from preclinical to phase I clinical trials. Expert Opinion on Investigational Drugs 29:9, pages 1005-1023.
Read now
Read now
Articles from other publishers (39)
Yahua Wu, Chengliu Lv, Mingqian Lin, Yaping Hong, Bin Du, Na Yao, Yingjiao Zhu, Xiaohui Ji, Jiancheng Li & Jinhuo Lai. (2023) Novel nomogram for predicting survival in advanced non-small cell lung cancer receiving anti-PD-1 plus chemotherapy with or without antiangiogenic therapy. Frontiers in Immunology 14.
Crossref
Crossref
Tingting Lu, Yufan Huang, Zhongjie Cai, Wangchun Lin, Xiaoxiao Chen, Ruijia Chen & Yingying Hu. (2023) The cost-effectiveness of cemiplimab plus chemotherapy as the first-line treatment for advanced non-small cell lung cancer. Frontiers in Pharmacology 14.
Crossref
Crossref
Da Qian, Yuhao Xu, Yihao Wu, Jie Qiu, Weimin Hong & Xuli Meng. (2023) Assessment of the safety and efficacy of combination chemotherapy and PD-1/PD-L1 inhibitor treatment of breast cancer: A meta-analysis. Chinese Medical Journal 136:14, pages 1663-1670.
Crossref
Crossref
T.A. Bogush, A.A. Basharin, A.M. Scherbakov, K.I. Chandran, A.L. Mikhailova, I.P. Romanov, E.A. Bogush & V.S. Kosorukov. (2023) TUMOR CELL PANEL WITH CHARACTERIZED EXPRESSION OF PD-L1 FOR PRECLINICAL STUDIES OF ANTICANCER DRUGS AND IMMUNE CHECKPOINT INHIBITORS INTERACTION. Lomonosov chemistry journal 64:№1, 2023, pages 26-34.
Crossref
Crossref
Xiaofang Wang, Xiao Mi, Teng Li & Chengcheng Li. (2023) Hyperprogressive disease after immune checkpoint inhibitor therapy in a patient with non‑small cell lung cancer who harbors a TGFBR2 mutation: A case report. Experimental and Therapeutic Medicine 25:5.
Crossref
Crossref
Hardeep Singh Tuli, Vivek K. Garg, Renuka Choudhary, Ashif Iqubal, Katrin Sak, Adesh K. Saini, Reena V. Saini, Kanupriya Vashishth, Kuldeep Dhama, Ranjan K. Mohapatra, Dhruv Sanjay Gupta & Ginpreet Kaur. (2022) Immunotherapeutics in lung cancers: from mechanistic insight to clinical implications and synergistic perspectives. Molecular Biology Reports 50:3, pages 2685-2700.
Crossref
Crossref
Hongxia Li, Qiuxia Fu, Tobias Achu Muluh, Shafiu A. Umar Shinge, Shaozhi Fu & JingBo Wu. (2023) The Application of Nanotechnology in Immunotherapy based Combinations
for Cancer Treatment. Recent Patents on Anti-Cancer Drug Discovery 18:1, pages 53-65.
Crossref
Crossref
Zhimin Wang, Tingting Wang, Xu Chen, Jing Cheng & Lijuan Wang. (2022) Pterostilbene regulates cell proliferation and apoptosis in non‐small‐cell lung cancer via targeting COX‐2. Biotechnology and Applied Biochemistry 70:1, pages 106-119.
Crossref
Crossref
Houssein Safa, Fawzi Abu Rous, Neel Belani, Hossein Borghaei, Shirish Gadgeel & Balazs Halmos. (2022) Emerging Biomarkers in Immune Oncology to Guide Lung Cancer Management. Targeted Oncology 18:1, pages 25-49.
Crossref
Crossref
T. A. Bogush, A. A. Basharina, A. M. Scherbakov, K. I. Chandran, A. L. Mikhailova, I. P. Romanov, E. A. Bogush & V. S. Kosorukov. (2023) Tumor Cell Panel with Characterized Expression of PD-L1 for Preclinical Studies of Anticancer Drugs and Immune Checkpoint Inhibitors’ Interaction. Moscow University Chemistry Bulletin 77:S1, pages S19-S24.
Crossref
Crossref
Chang Li, Chen Tian, Yulan Zeng, Jinyan Liang, Qifan Yang, Feifei Gu, Yue Hu & Li Liu. (2022) Machine learning and bioinformatics analysis revealed classification and potential treatment strategy in stage 3–4 NSCLC patients. BMC Medical Genomics 15:1.
Crossref
Crossref
Yi Guo, Quan Li, Rongmu Xia & Chuanshu Cai. (2022) Farrerol exhibits inhibitory effects on lung adenocarcinoma cells by activating the mitochondrial apoptotic pathway. Journal of Biochemical and Molecular Toxicology 36:10.
Crossref
Crossref
Shanshan Peng, Yu Xiao, Xinjun Li & Zhanling Wu. (2022) A nomogram for predicting overall survival rate in patients with brain metastatic non-small cell lung cancer. Medicine 101:38, pages e30824.
Crossref
Crossref
Vajihe Akbari, Elham Hejazi, Mohsen Minaiyan, Jaber Emami, Afsaneh Lavasanifar & Mahboubeh Rezazadeh. (2022) An injectable thermosensitive hydrogel/nanomicelles composite for local chemo-immunotherapy in mouse model of melanoma. Journal of Biomaterials Applications 37:3, pages 551-562.
Crossref
Crossref
Jonatan Lindqvist, Antti Jekunen, Eero Sihvo, Mikael Johansson & Heidi Andersén. (2022) Effect of adherence to treatment guidelines on overall survival in elderly non-small-cell lung cancer patients. Lung Cancer 171, pages 9-17.
Crossref
Crossref
Alessio Cortellini, Biagio Ricciuti, Hossein Borghaei, Abdul Rafeh Naqash, Antonio D'Alessio, Claudia A. M. Fulgenzi, Alfredo Addeo, Giuseppe L. Banna & David James Pinato. (2022)
Differential prognostic effect of systemic inflammation in patients with non–small cell lung cancer treated with immunotherapy or chemotherapy: A post hoc analysis of the phase 3
OAK
trial
. Cancer 128:16, pages 3067-3079.
Crossref
Crossref
Yunmi Ko, Yeon Ho Jeong & Jun Ah Lee. (2022) Therapeutic Potential of Ex Vivo Expanded γδ T Cells against Osteosarcoma Cells. Cells 11:14, pages 2164.
Crossref
Crossref
Evangelos Tzoras, Ioannis Zerdes, Nikos Tsiknakis, Georgios C. Manikis, Artur Mezheyeuski, Jonas Bergh, Alexios Matikas & Theodoros Foukakis. (2022) Dissecting Tumor-Immune Microenvironment in Breast Cancer at a Spatial and Multiplex Resolution. Cancers 14:8, pages 1999.
Crossref
Crossref
Weizheng Fu, Qingsheng Kan, Bin Li & Xiaoming Zhang. (2022) Prognosis Model of Advanced Non-Small-Cell Lung Cancer Based on Max-Min Hill-Climbing Algorithm. Computational and Mathematical Methods in Medicine 2022, pages 1-10.
Crossref
Crossref
James J. Saller & Theresa A. Boyle. (2022) Molecular Pathology of Lung Cancer. Cold Spring Harbor Perspectives in Medicine 12:3, pages a037812.
Crossref
Crossref
Gisela María Suárez, Mauricio Catalá, Yadira Peña, Susana Portela, Ana Laura Añé-Kourí, Amnely González, Patricia Lorenzo-Luaces, Manuel Díaz, María de los A. Molina, Karla Pereira, Jenysbel de la C. Hernández, Raúl Ramos, Mary Carmen Reyes, Nuris Ledón, Zaima Mazorra, Tania Crombet, Agustin Lage & Danay Saavedra. (2022) Thymic Polypeptide Fraction Biomodulina T Decreases Exhausted and Terminally Differentiated EMRA T Cells in Advanced Lung Cancer Patients Treated With Platinum-Based Chemotherapy. Frontiers in Oncology 12.
Crossref
Crossref
Ray D. Page, Leylah M. Drusbosky, Hiba Dada, Victoria M. Raymond, Davey B. Daniel, Stephen G. Divers, Karen L. Reckamp, Miguel A. Villalona-Calero, Daniel Dix, Justin I. Odegaard, Richard B. Lanman, Vassiliki A. Papadimitrakopoulou & Natasha B. Leighl. (2022) Clinical Outcomes for Plasma-Based Comprehensive Genomic Profiling Versus Standard-of-Care Tissue Testing in Advanced Non–Small Cell Lung Cancer. Clinical Lung Cancer 23:1, pages 72-81.
Crossref
Crossref
Guiyuan Xiang, Lingna Gu, Xuan Chen, Fan Wang, Bohua Chen, Jie Zhao, Yun Lu, Feng Chang & Yumei Zhu. (2021) Economic Evaluation of First-Line Camrelizumab for Advanced Non-small-cell Lung Cancer in China. Frontiers in Public Health 9.
Crossref
Crossref
Chun-Hua Zhou, Feng Yang, Wen-Juan Jiang, Yong-Chang Zhang, Hai-Yan Yang, Liang Zeng, Li Liu, Yi Xiong, Fan-Xu Zeng, Zhan Wang & Nong Yang. (2021) Efficacy and Safety of Different Doses of Bevacizumab Combined With Pemetrexed and Platinum in First-Line Treatment of Advanced NSCLC: A Retrospective-Real World Study. Frontiers in Pharmacology 12.
Crossref
Crossref
Beibei Guo, Elizabeth Garrett-Mayer & Suyu Liu. (2021) A Bayesian Phase I/II Design for Cancer Clinical Trials Combining an Immunotherapeutic Agent with a Chemotherapeutic Agent. Journal of the Royal Statistical Society Series C: Applied Statistics 70:5, pages 1210-1229.
Crossref
Crossref
Marika Saar, Jaanika Narits, Laura Mägi, Hardi Aaspõllu, Annett Vapper, Marju Kase, Ave Minajeva, Tõnu Vooder, Hannes Tamm, Maksim Buldakov, Darja Lavõgina & Jana Jaal. (2021) Expression of immune checkpoint PD‑1 in non‑small cell lung cancer is associated with tumor cell DNA‑dependent protein kinase. Molecular and Clinical Oncology 15:4.
Crossref
Crossref
Luigi Della Gravara, Ciro Battiloro, Antonietta Letizia, Rosa Cantile, Vito D'Agnano, Giacomo Sica & Danilo Rocco. (2021) Emerging Biomarkers for the Selection of Advanced NSCLC-Affected Immunotherapy Patients. Journal of Molecular Pathology 2:2, pages 197-206.
Crossref
Crossref
Makoto Nishio, Haruhiro Saito, Koichi Goto, Satoshi Watanabe, Naoko Sueoka‐Aragane, Yusuke Okuma, Kazuo Kasahara, Kenichi Chikamori, Yuki Nakagawa & Tomohisa Kawakami. (2021) IMpower132: Atezolizumab plus platinum‐based chemotherapy vs chemotherapy for advanced NSCLC in Japanese patients. Cancer Science 112:4, pages 1534-1544.
Crossref
Crossref
A. Camerini, A. Morabito, A. Montanino, R. Bernabé, F. Grossi, R. Ramlau, T.-E. Ciuleanu, G.-L. Ceresoli, G. Pasello, F. de Marinis, J. Bosch-Barrera, P. Laundreau, S. Gautier, C. Ta Thanh Minh & D. Kowalski. (2021) Metronomic oral vinorelbine in previously untreated advanced non-small-cell lung cancer patients unfit for platinum-based chemotherapy: results of the randomized phase II Tempo Lung trial. ESMO Open 6:2, pages 100051.
Crossref
Crossref
Zhen Zeng, Hui Yi Chew, Jazmina G. Cruz, Graham R. Leggatt & James W. Wells. (2021) Investigating T Cell Immunity in Cancer: Achievements and Prospects. International Journal of Molecular Sciences 22:6, pages 2907.
Crossref
Crossref
Galina F. Medvedeva, Daria O. Kuzmina, Julia Nuzhina, Alexander A. Shtil & Marina S. Dukhinova. (2021) How Macrophages Become Transcriptionally Dysregulated: A Hidden Impact of Antitumor Therapy. International Journal of Molecular Sciences 22:5, pages 2662.
Crossref
Crossref
Amila Suraweera, Pascal H. G. Duijf, Christian Jekimovs, Karsten Schrobback, Cheng Liu, Mark N. Adams, Kenneth J. O’Byrne & Derek J. Richard. (2021) COMMD1, from the Repair of DNA Double Strand Breaks, to a Novel Anti-Cancer Therapeutic Target. Cancers 13:4, pages 830.
Crossref
Crossref
Pei-Pei Zhang, Juan Wang, Da-Zhi Ding, Li Zhang, Chun Cheng & Da-Ke Chen. (2021) Efficacy and safety of PD-1/PD-L1 inhibitors combined with CTLA-4 inhibitor versus chemotherapy for advanced lung cancer. Medicine 100:35, pages e27121.
Crossref
Crossref
Bardia Yousefi, Sharyn I. KatzLeonid Roshkovan. (2020) Radiomics: A Path Forward to Predict Immunotherapy Response in Non–Small Cell Lung Cancer. Radiology: Artificial Intelligence 2:5, pages e200075.
Crossref
Crossref
Amila Suraweera, Alex Duff, Mark N. Adams, Christian Jekimovs, Pascal H. G. Duijf, Cheng Liu, Matthew McTaggart, Sam Beard, Kenneth J. O’Byrne & Derek J. Richard. (2020) Defining COMMD4 as an anti-cancer therapeutic target and prognostic factor in non-small cell lung cancer. British Journal of Cancer 123:4, pages 591-603.
Crossref
Crossref
Angela M. Jarrett, Danial Faghihi, David A. HormuthIIII, Ernesto A. B. F. Lima, John Virostko, George Biros, Debra Patt & Thomas E. Yankeelov. (2020) Optimal Control Theory for Personalized Therapeutic Regimens in Oncology: Background, History, Challenges, and Opportunities. Journal of Clinical Medicine 9:5, pages 1314.
Crossref
Crossref
Luigi Della Gravara, Ciro Battiloro, Rosa Cantile, Antonietta Letizia, Fabiana Vitiello, Vincenzo Montesarchio & Danilo Rocco. (2020) Chemotherapy and/or immune checkpoint inhibitors in NSCLC first-line setting: what is the best approach?. Lung Cancer Management 9:1.
Crossref
Crossref
Georgia Gomatou, Vasilios Tzilas, Elias Kotteas, Konstantinos Syrigos & Demosthenes Bouros. (2020) Immune Checkpoint Inhibitor-Related Pneumonitis. Respiration 99:11, pages 932-942.
Crossref
Crossref
Alessandro Leonetti, Birgit Wever, Giulia Mazzaschi, Yehuda G. Assaraf, Christian Rolfo, Federico Quaini, Marcello Tiseo & Elisa Giovannetti. (2019) Molecular basis and rationale for combining immune checkpoint inhibitors with chemotherapy in non-small cell lung cancer. Drug Resistance Updates 46, pages 100644.
Crossref
Crossref